Argenx SE. (9/3/21). "Press Release: Argenx to Present at Upcoming Investor Conferences". Breda.

	Organisation	Argenx SE (Euronext + Nasdaq: ARGX)
	Group	Argenx (Argen-X) (Group)
	Organisation 2	SVB Leerink LLC
	Today	Leerink Partners (Group)
	Group	Leerink Partners (Group)
	Product	KBC Life Sciences & Biotech Virtual Conference 2021
	Product 2	Morgan Stanley Global Healthcare Conference 2021 DIGITAL
	Index term	Argenx–Bank of America: investor conference, 202109 supply service Argenx presents at BofA Global Healthcare Conference 2021
	Index term 2	Argenx–SVB: investor conference, 202109 supply service Argenx participates in SVB Leerink CybeRx Series 1x1 Event
	Person	Comijn, Joke (Argen-X 201704 Corp Communications Manager)
	Person 2	DelGiacco, Beth (Argenx 201806– VP Investor Relations before Stern IR)

argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences:

> KBC Life Sciences & Biotech Virtual Conference. Management will participate in investor meetings on Tuesday, September 7, 2021.

> Morgan Stanley Global Healthcare Conference. Fireside chat on Friday, September 10, 2021 at 4:15 p.m. ET.

> BofA Global Healthcare Conference. Fireside chat on Thursday, September 16, 2021 at 4:45 p.m. BST.

> SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event. Management will participate in investor meetings on Wednesday, September 22, 2021.

Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn.

For further information, please contact:

Media:

Kelsey Kirk
kkirk@argenx.com

Joke Comijn (EU)
jcomijn@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com

Record changed: 2023-06-05